Literature DB >> 16200640

Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?

Alan Smyth1.   

Abstract

Pulmonary infection with Staphylococcus aureus occurs in young children with cystic fibrosis, and may contribute to the cycle of infection, inflammation, and destruction of lung tissue which leads to bronchiectasis. Practice guidelines in North America and the UK differ greatly with regard to the advice given on prescribing prophylactic antistaphylococcal antibiotics to young children with cystic fibrosis. This article reviews the evidence behind these guidelines, and suggests a pragmatic approach to clinical practice. The implications for research are also discussed, and suggestions are made for clinical trials to inform future guidelines. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16200640     DOI: 10.1002/ppul.20305

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  10 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.

Authors:  Lucas R Hoffman; Eric Déziel; David A D'Argenio; François Lépine; Julia Emerson; Sharon McNamara; Ronald L Gibson; Bonnie W Ramsey; Samuel I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

3.  Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.

Authors:  Daniel J Wolter; Julia C Emerson; Sharon McNamara; Anne M Buccat; Xuan Qin; Elizabeth Cochrane; Laura S Houston; Geraint B Rogers; Peter Marsh; Karandeep Prehar; Christopher E Pope; Marcella Blackledge; Eric Déziel; Kenneth D Bruce; Bonnie W Ramsey; Ronald L Gibson; Jane L Burns; Lucas R Hoffman
Journal:  Clin Infect Dis       Date:  2013-04-26       Impact factor: 9.079

4.  [Cystic fibrosis and associated complications].

Authors:  C Schwarz; D Staab
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

5.  Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

Authors:  Hara Levy; Leslie A Kalish; Carolyn L Cannon; K Christopher García; Craig Gerard; Don Goldmann; Gerald B Pier; Scott T Weiss; A A Colin
Journal:  Pediatr Pulmonol       Date:  2008-05

Review 6.  Exacerbations in cystic fibrosis: 2 . prevention.

Authors:  Scott C Bell; Philip J Robinson
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

Review 7.  Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis.

Authors:  Molla Imaduddin Ahmed; Saptarshi Mukherjee
Journal:  Cochrane Database Syst Rev       Date:  2018-07-27

8.  Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients.

Authors:  Heather G Ahlgren; Andrea Benedetti; Jennifer S Landry; Joanie Bernier; Elias Matouk; Danuta Radzioch; Larry C Lands; Simon Rousseau; Dao Nguyen
Journal:  BMC Pulm Med       Date:  2015-06-21       Impact factor: 3.317

9.  Staphylococcus aureus Pathogenicity in Cystic Fibrosis Patients-Results from an Observational Prospective Multicenter Study Concerning Virulence Genes, Phylogeny, and Gene Plasticity.

Authors:  Jonas Lange; Kathrin Heidenreich; Katharina Higelin; Kristina Dyck; Vanessa Marx; Christian Reichel; Willem van Wamel; Martijn den Reijer; Dennis Görlich; Barbara C Kahl
Journal:  Toxins (Basel)       Date:  2020-04-26       Impact factor: 4.546

10.  Piggyback-the-Winner in host-associated microbial communities.

Authors:  Cynthia B Silveira; Forest L Rohwer
Journal:  NPJ Biofilms Microbiomes       Date:  2016-07-06       Impact factor: 7.290

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.